Simponi Indications/Uses

SIMPONI Solution for Injection: Rheumatoid arthritis (RA): SIMPONI, by subcutaneous (SC) administration, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate; the treatment of active, severe and progressive rheumatoid arthritis in adult patients not previously treated with MTX.
SIMPONI, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
Psoriatic arthritis (PsA): SIMPONI, by subcutaneous (SC) administration, alone or in combination with MTX, is indicated for: The treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
SIMPONI has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.
Axial spondyloarthritis: Ankylosing spondylitis (AS): SIMPONI, by subcutaneous (SC) administration, is indicated for: The treatment of active ankylosing spondylitis in adult patients when the response to conventional therapy has been inadequate.
Non-radiographic axial spondyloarthritis (nr-Axial SpA): SIMPONI, by subcutaneous (SC) administration, is indicated for: the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Ulcerative colitis (UC): SIMPONI, by subcutaneous (SC) administration, is indicated for: The treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
SIMPONI IV 12.5mg/1ml Concentrate for Solution for Infusion: Rheumatoid arthritis (RA): SIMPONI, by IV administration, in combination with MTX, is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.
SIMPONI, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.
Ankylosing spondylitis (AS): SIMPONI, by IV administration, is indicated for: the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to conventional therapies.
Psoriatic arthritis (PsA): SIMPONI, by IV administration, alone or in combination with MTX, is indicated for: the treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.